Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis - ScienceDirect
Figure 4, Illustration of the Sensitivity of LDV/SOF Sustained Virologic Response to One (LDV/SOF 22/1) and Two (LDV/SOV 22/2) Additional Data Points - Ledipasvir/Sofosbuvir (Harvoni) - NCBI Bookshelf
EVALUACIÓN DE LA EFICACIA DE NUEVOS ANTIVÍRICOS DE ACCIÓN DIRECTA EN COMBINACIÓN CON SOFOSBUVIR FRENTE A GENOTIPO 1 DE VHC
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/ LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV) | Scientific Reports
HCV-Trials.com : A regularly updated website with all most recent clinical trials data in HCV infection
HepDart) Ledipasvir/Sofosbuvir (LDV/SOF) for 8 Weeks in Genotype 1 (GT1) Treatment-Naïve (TN) Non-Cirrhotic (NC) Patients with HCV Viral load (VL) <6 million IU/ml (6M); A Comparative Analysis of the Phase-3 ION-3 Efficacy
Cost-utility Analysis of Second-generation Direct-acting Antivirals for Hepatitis C | Hepatitis Monthly | Full Text
Combinación de ledipasvir/sofosbuvir como tratamiento de la infección crónica por hepatitis C | Anales de Pediatría
Informe de Posicionamiento Terapéutico de ledipasvir/sofosbuvir (Harvoni®)
Pooling SAE rates of SOFL/LDV regimen on HCV genotype 6. SAE, serious... | Download Scientific Diagram
Informe de Posicionamiento Terapéutico de ledipasvir/sofosbuvir (Harvoni®)
Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b - Zakalashvili - 2021 - Hepatology Research - Wiley Online Library
Informe d'avaluació de resultats del tractament antiviral de l'hepatitis C a l'any 2018
Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: A retrospective study with prospectively collected data | PLOS ONE
Incremental cost and effectiveness of SOF/VEL relative to SOF/LDV in... | Download Scientific Diagram
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study | PLOS ONE
ION-1 Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection. - ppt download
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China
Treatment groups by regimen. SOF, sofosbuvir; LDV, ledipasvir; SIM,... | Download Scientific Diagram
ION-3 Study: LDV/SOF + RBV for naïve genotype 1 - ppt download
Treatment outcomes for SOF/LDV without RBV for HCV genotype 1 (1a, 1b,... | Download Scientific Diagram
